Literature DB >> 11972356

CTLA-4 negative signaling via lipid rafts: A new perspective.

Christopher E Rudd1, Margarita Martin, Helga Schneider.   

Abstract

Proper function of the immune system requires that activation of T cells is precisely regulated. Responses to the T cell receptor are modulated by signals from other receptors. CTLA-4 (cytotoxic T lymphocyte antigen-4, also called CD152), for example, inhibits cytokine production and proliferation of T cells. Activation of T cells is associated with the accumulation of signaling proteins in lipd rafts--microdomains of the plasma membrane enriched in cholesterol and glycosphingolipds. Rudd et al. discuss evidence that CTLA-4 might inhibit cytokine production and T cell proliferation by limiting the assembly of lipid rafts, which are critical to the formation of a functional immunological synapse between antigen-presenting cells and T cells.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11972356     DOI: 10.1126/stke.2002.128.pe18

Source DB:  PubMed          Journal:  Sci STKE        ISSN: 1525-8882


  9 in total

1.  CTLA-4 up-regulation of lymphocyte function-associated antigen 1 adhesion and clustering as an alternate basis for coreceptor function.

Authors:  Helga Schneider; Elke Valk; Silvy da Rocha Dias; Bin Wei; Christopher E Rudd
Journal:  Proc Natl Acad Sci U S A       Date:  2005-08-26       Impact factor: 11.205

2.  Murine regulatory T cells differ from conventional T cells in resisting the CTLA-4 reversal of TCR stop-signal.

Authors:  Yuning Lu; Helga Schneider; Christopher E Rudd
Journal:  Blood       Date:  2012-10-09       Impact factor: 22.113

3.  CTLA-4 disrupts ZAP70 microcluster formation with reduced T cell/APC dwell times and calcium mobilization.

Authors:  Helga Schneider; Xin Smith; Hebin Liu; Georges Bismuth; Christopher E Rudd
Journal:  Eur J Immunol       Date:  2008-01       Impact factor: 5.532

4.  Dlgh1 coordinates actin polymerization, synaptic T cell receptor and lipid raft aggregation, and effector function in T cells.

Authors:  June L Round; Tamar Tomassian; Min Zhang; Viresh Patel; Stephen P Schoenberger; M Carrie Miceli
Journal:  J Exp Med       Date:  2005-02-07       Impact factor: 14.307

Review 5.  Diverse mechanisms regulate the surface expression of immunotherapeutic target ctla-4.

Authors:  Helga Schneider; Christopher E Rudd
Journal:  Front Immunol       Date:  2014-12-04       Impact factor: 7.561

Review 6.  A New VISTA on combination therapy for negative checkpoint regulator blockade.

Authors:  Jie Deng; Isabelle Le Mercier; Anna Kuta; Randolph J Noelle
Journal:  J Immunother Cancer       Date:  2016-12-20       Impact factor: 13.751

Review 7.  CD28 and CTLA-4 coreceptor expression and signal transduction.

Authors:  Christopher E Rudd; Alison Taylor; Helga Schneider
Journal:  Immunol Rev       Date:  2009-05       Impact factor: 12.988

Review 8.  CTLA-4 trafficking and surface expression.

Authors:  Elke Valk; Christopher E Rudd; Helga Schneider
Journal:  Trends Immunol       Date:  2008-05-09       Impact factor: 16.687

9.  PAG/Cbp suppression reveals a contribution of CTLA-4 to setting the activation threshold in T cells.

Authors:  Michal Smida; Clemens Cammann; Slavyana Gurbiel; Nadja Kerstin; Holger Lingel; Sabine Lindquist; Luca Simeoni; Monika C Brunner-Weinzierl; Miloslav Suchanek; Burkhart Schraven; Jonathan A Lindquist
Journal:  Cell Commun Signal       Date:  2013-04-19       Impact factor: 5.712

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.